‘One-of-a-Kind’ $10 Million Psychedelic Research Center Comes to NYU
NYU will open a $10 million psychedelic research center to further its work in using psychedelic substances to treat mental health issues.
Entries by Jill Ettinger
Psychedelic Business News Spotlight: February 19, 2021
This week in psychedelic business news: MindMed acquires a digital health company, Mindest Pharma goes public, new MDMA treatment for PTSD, and more.
Psychedelic Business News Spotlight: February 12, 2021
This week in Psychedelic business news: MindMed has a new partner, Mydecine closes a funding round, and the world’s first legal psilocybin cultivation facility launches.
Study: 69% of Suicidal Patients Saw ‘Significant’ Improvement With Ketamine Therapy
A new study links ketamine therapy to a significant reduction in thoughts of suicide for 69 percent of study participants.
Psychedelic Business News Spotlight: February 5, 2021
This week in psychedelic business news, Super Mario’s magic mushroom gets a new use, Mindset files three patents, Bright Minds goes public, and more.
2 Massachusetts Cities Have Decriminalized Psychedelics in the Last Month
Two Massachusetts cities have decriminalized psychedelics since the start of 2021. Cambridge and Somerville say the benefits outweigh the risks.
The World’s First Psychedelic ETF Just Launched: Here’s Why That Matters
The Horizons Psychedelic ETF launched on the Canadian NEO stock exchange last month. Here’s what that means for the industry, and the future.
Psychedelic Business News Spotlight: January 29, 2021
This week in psychedelic business news, Psyence Group’s psilocybin harvest, NeonMind’s new CEO, and Mydecine sponsors new research.
Hawaii Moves to Legalize Psilocybin Treatment
Hawaii may soon legalize psilocybin therapy for the treatment of a range of mental health issues, according to proposed legislation.
Psychedelic Business News Spotlight: January 22, 2021
This week in psychedelic industry news: the first psychedelic stock index, new products, mergers, and funds.
